Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2012 (2012), Article ID 581363, 10 pages
Review Article

Lipoplatin Formulation Review Article

1First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
2Regulon Inc. and Regulon AE, Afxentiou 7, Alimos, 17455 Athens, Greece

Received 29 May 2011; Accepted 24 June 2011

Academic Editor: Rassoul Dinarvand

Copyright © 2012 G. P. Stathopoulos and T. Boulikas. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Patented platform technologies have been used for the liposomal encapsulation of cisplatin (Lipoplatin) into tumor-targeted 110 nm (in diameter) nanoparticles. The molecular mechanisms, preclinical and clinical data concerning lipoplatin, are reviewed here. Lipoplatin has been successfully administered in three randomized Phase II and III clinical trials. The clinical data mainly include non-small-cell lung cancer but also pancreatic, breast, and head and neck cancers. It is anticipated that lipoplatin will replace cisplatin as well as increase its potential applications. For the first time, a platinum drug has shown superiority to cisplatin, at least in non-squamous non-small-cell lung cancer as reported in a Phase III study which documented a simultaneous lowering of all of the side effects of cisplatin.